McAdam LLC Purchases Shares of 395 Thermo Fisher Scientific Inc. (NYSE:TMO)

McAdam LLC acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 395 shares of the medical research company’s stock, valued at approximately $210,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in TMO. Mather Group LLC. raised its position in Thermo Fisher Scientific by 5.6% in the 4th quarter. Mather Group LLC. now owns 3,099 shares of the medical research company’s stock valued at $1,645,000 after buying an additional 163 shares during the last quarter. Monumental Financial Group Inc. raised its holdings in shares of Thermo Fisher Scientific by 4.6% in the fourth quarter. Monumental Financial Group Inc. now owns 2,196 shares of the medical research company’s stock valued at $1,166,000 after purchasing an additional 96 shares during the last quarter. Silver Oak Securities Incorporated acquired a new position in Thermo Fisher Scientific during the fourth quarter worth $240,000. Magnus Financial Group LLC grew its position in Thermo Fisher Scientific by 2.9% in the fourth quarter. Magnus Financial Group LLC now owns 3,076 shares of the medical research company’s stock valued at $1,633,000 after purchasing an additional 88 shares in the last quarter. Finally, Little House Capital LLC lifted its position in Thermo Fisher Scientific by 2.8% during the 4th quarter. Little House Capital LLC now owns 4,590 shares of the medical research company’s stock worth $2,436,000 after buying an additional 127 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Down 1.4 %

TMO opened at $568.74 on Wednesday. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $603.82. The company has a market capitalization of $217.09 billion, a P/E ratio of 36.48, a P/E/G ratio of 2.40 and a beta of 0.80. The stock has a fifty day moving average of $574.58 and a 200-day moving average of $531.67. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. The firm had revenue of $10.35 billion during the quarter, compared to the consensus estimate of $10.14 billion. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 21.59 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were given a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date of this dividend was Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.01%.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. JPMorgan Chase & Co. upped their target price on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a report on Thursday, April 25th. Sanford C. Bernstein reissued a “market perform” rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. HSBC upped their price target on shares of Thermo Fisher Scientific from $660.00 to $670.00 and gave the stock a “buy” rating in a research report on Tuesday. The Goldman Sachs Group boosted their price objective on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Finally, Barclays lifted their price target on Thermo Fisher Scientific from $590.00 to $615.00 and gave the stock an “equal weight” rating in a report on Thursday, April 25th. Five research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $607.35.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the completion of the sale, the chief executive officer now owns 49,155 shares of the company’s stock, valued at $27,311,992.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total value of $5,556,300.00. Following the transaction, the chief executive officer now owns 49,155 shares in the company, valued at approximately $27,311,992.65. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction dated Friday, April 26th. The stock was sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the completion of the transaction, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at approximately $7,430,359.02. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 52,277 shares of company stock worth $29,649,264. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.